In contrast, SARAF’s trend toward lower expression in HCC tumors (96.21 TPM vs. 110.04 TPM) suggests a distinct role as a negative regulator compared to STIM1 and Orai1, which are often overexpressed in malignancies. The gene discussed is ORAI1; the disease is hepatocellular carcinoma.